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Although several human clinical trials using various bone marrow-derived cell types for cirrhotic or decom-
pensated patients have reported a short-term benefit, long-term follow-up data are limited. We analyzed the 
long-term clinical outcomes of autologous bone marrow cell infusion (ABMI) for decompensated liver cir-
rhosis (LC). Patients enrolled in a pilot single-armed ABMI study were followed up more than 5 years. Bone 
marrow-derived mononuclear cells (BM-MNCs) from decompensated LC were harvested and after processing 
were infused into a peripheral vein. The laboratory test results and long-term clinical course including liver 
transplantation (LT), development of cancer, cause of death, and survival after ABMI were analyzed. Nineteen 
patients were followed up for a median of 66 months after ABMI. Liver function, including serum levels of 
albumin and Child–Pugh (CP) score, was improved at the 1-year follow-up. Liver volume was significantly 
greater, cirrhosis was sustained, and collagen content was decreased at the 6-month follow-up. Five years after 
ABMI, five patients (26.3%) maintained CP class A without LT or death, and five patients (26.3%) had under-
gone elective LT. Hepatocellular carcinoma (HCC) occurred in five patients (26.3%), and lymphoma and colon 
cancer occurred in one patient each. Three patients (15.8%) were lost to follow-up at months 22, 31, and 33, 
respectively, but maintained CP class A until their last follow-up. Five patients expired due to infection. While 
improved liver function was maintained in some patients for more than 5 years after ABMI, other patients 
developed HCC. Further studies of long-term follow-up cohorts after cell therapy for LC are warranted.
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INTRODUCTION
The end point of liver disease, irrespective of its cause, 
is liver cirrhosis (LC). Because fibrous scars hardly dis-
appear, a cirrhotic liver does not return to a normal state. 
Before decompensation, control of the underlying liver 
disease is important to recover to some degree. After 
de compensation, patients suffer from repeated and con-
tinuous complications, including hepatocellular carci-
noma (HCC). At present, liver transplantation (LT) is the 
only treatment option for patients with HCC.
Although antifibrotic drugs have been developed, 
their efficacy is limited. Research into bone marrow cells 
(BMCs) has facilitated the application of cellular thera-
peutics. In hepatology, hepatocytes from BM have been 
found in mouse1,2 and human3,4 livers after BMC trans-
plantation, suggesting that BMCs could contribute to 
liver regeneration. The fate of BMCs injected into fibrotic 
or injured livers has been investigated5,6. Injected cells 
migrate to the fibrous area, penetrate into cords of hepa-
tocytes, and produce enzymes that ameliorate fibrosis6. 
Together with BMCs, mesenchymal stem cells (MSCs) 
have been investigated. Following enhancement of their 
immunomodulatory and antifibrotic effects in other organ 
systems, application of MSCs to treat liver fibrosis has 
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shown positive results7–10. For clinical application, MSCs 
must undergo in vitro selection and culture. A clinical 
trial using MSCs, therefore, could not start at the initia-
tory stage in cell therapy until assurance of safety during 
in vitro manipulation. Although early studies had sug-
gested transdifferentiation of BMCs or MSCs into hepa-
tocytes, mechanisms of action remain poorly understood. 
Paracrine effects supporting hepatocyte function and 
liver regeneration and immune modulation are thought to 
be possible mechanisms11.
For clinical application, cell therapy similar to autolo-
gous BM stem cell transplantation was first evaluated12, 
as this procedure has long been applied to the treatment 
of hematologic disease. Subsequent clinical trials of 
autologous BMCs selected by means of surface markers13 
or injected through the hepatic artery14 or the portal vein15 
have reported efficacy in terms of liver regeneration after 
liver surgery or transient improvement of hepatic func-
tion. Further trials using BMCs16–18, mobilized peripheral 
blood mononuclear cells (PBMNCs)19,20, BM-derived 
endothelial progenitor cells21, or BM-derived MSCs (BM- 
MSCs)22–24 for LC have reported positive short-term 
results, but the beneficial effects lasted for less than 
2 years23. However, no study has evaluated maintenance 
of liver function, survival, and HCC development in such 
patients at ³3 years after treatment.
We previously reported the preliminary outcomes 
of patients who underwent autologous bone marrow 
cell infusion (ABMI) for advanced LC25. Together with 
gradual improvement of liver function and volume, serial 
liver biopsies showed an activated progenitor cell com-
partment after ABMI. A planned single-armed pilot study 
has been completed, and enrolled patients were followed 
up for more than 5 years. In this study, the long-term clin-
ical outcomes of patients who underwent ABMI therapy 
for decompensated LC were analyzed.
MATERIALS AND METHODS
Patients
Patients enrolled in a pilot trial of ABMI therapy for 
decompensated LC between June 2006 and February 
2011 were analyzed. All patients provided informed 
consent and met the following inclusion criteria: age 
18–75 years, biopsy-proven LC with Child–Pugh (CP) 
class B or C, platelet count ³50,000/µl and total bilirubin 
£3.0 mg/dl, and without evidence of HCC on magnetic 
resonance imaging (MRI). Patients who had a history of 
HCC without recurrence 2 years after curative treatment 
were eligible. Patients with a medical condition that made 
them ineligible for general anesthesia during BM collec-
tion were excluded. Patients maintained all medications, 
with the exception of intravenous albumin. The diuretic 
dose was adjusted according to the patient’s volume 
status after ABMI. Biochemical tests were performed 
for 12 months after ABMI. Thereafter, patients were 
followed up according to their individual clinic visit 
schedule. Long-term follow-up data were collected ret-
rospectively. In patients who consented to follow-up, LT 
and development of malignancy, including hepatic func-
tion reserve, were monitored. To avoid potential bias, 
ABMI was considered to have failed in patients who 
underwent LT.
This study conformed to the ethical guidelines of 
the Declaration of Helsinki and was approved by the 
institutional review board (IRB) of Severance Hospital 
in the Yonsei University Health System (No. 4-2006-
0087). This study was conducted with the cooperation of 
Yamaguchi University Graduate School of Medicine in 
Japan, under a memorandum of understanding.
Cell Preparation
Under general anesthesia, 500–750 ml of BM was 
aspirated from both ilia and collected in a plastic bag 
containing heparin for harvesting of marrow for BMC 
transplantation. Collected BM was filtered to remove 
fat and bony particles using a collection and gravity-
flow filtration system (BM collection kit; Fenwal Inc., 
Lake Zurich, IL, USA). Red blood cells and plasma 
were depleted, and mononuclear cells were collected 
in a closed system using a COBE 2991 Cell Processor 
(Gambro, Lakewood, CO, USA). The final volume was 
~100 ml. Processed cells were enumerated and tested 
for viability and contamination. Fluorescence-activated 
cell sorting (FACS) analysis was performed using a 
flow cytometer (Cytomics FC 500; Beckman Coulter, 
Inc., Brea, CA, USA) to evaluate cell populations using 
cell surface markers [cluster of differentiation (CD) 
34, CD45, and CD133 (Miltenyi Biotec Inc., Auburn, 
CA, USA); CD117 (Immunotech, Beckman Coulter, 
Marseille, France)]. The final cell product was infused 
into a peripheral vein over a 1-h period.
Clinical Evaluation
After obtaining informed consent, screening tests were 
performed to meet the inclusion criteria. Twelve months 
of clinical follow-up with serial evaluations was con-
ducted. Follow-up visits were scheduled weekly for 
2 weeks, monthly for the first 6 months, and then every 
3 months for the following 6 months. At each visit, labo-
ratory parameters (complete blood count, serum levels 
of blood glucose, total protein, albumin, bilirubin, amin-
otransferases, alkaline phosphatase, g-glutamyl transpep-
tidase, urea, creatinine, cholesterol, a-fetoprotein levels, 
and prothrombin time) were evaluated. Indocyanine 
green clearance testing was performed before and 6 and 
12 months after ABMI.
Liver MRI and biopsies were conducted before 
and 1, 3, and 6 months after ABMI. All MRI scans to 
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screen for HCC and quantify ascites and liver volume 
were performed using a 1.5-T MRI scanner (Gyroscan 
Intera; Philips Medical Systems, Best, The Netherlands). 
Routine T1-weighted gradient echo, T2-weighted turbo 
spin echo, T2*-weighted gradient echo, and three-phase, 
dynamic three-dimensional (3D) T1-weighted images after 
injection of gadobenate dimeglumine (dose, 0.1 mmol/ kg 
body weight; MultiHance; Bracco SpA, Milan, Italy) 
were obtained. Total liver volume was measured using 
commercially available image postprocessing software 
(Voxel plus 2; Mevisys, Daeduk, South Korea) with one 
radiologist applying the summation of areas technique 
using a 10-mm reconstruction thickness. The radiologist 
was blinded to the patients’ clinical information.
Liver biopsies were performed using an ultrasound-
guided 16-gauge gun. Transjugular liver biopsy was 
attempted as an alternative method in cases with mas-
sive ascites or a high risk of bleeding. The biopsied 
liver tissues were routinely processed and stained with 
hematoxylin and eosin (H&E) and Masson’s trichrome. 
Staining was performed by an autostainer (Symphony 
staining instrument; Ventana Medical Systems, Tucson, 
AZ, USA). Unstained slides, available after routine his-
tologic evaluation, were analyzed using a computer- 
assisted, staining-free method for liver fibrosis assess-
ment by Genesis® 200 (Histoindex, Singapore)26.
Statistical Analysis
Serial data from baseline to follow-up visits after 
ABMI were analyzed. After normality test of data, con-
tinuous variables are presented as means ± standard devi-
ations or median (range) accordingly, and categorical 
variables are presented as absolute values and percent-
ages. Paired-sample t-tests were used to compare values. 
Data of liver volume did not follow normal distribution; 
change of liver volume was compared with Wilcoxon’s 
matched-pairs signed-ranks test. All statistical proce-
dures were conducted using PASW Statistics 17.0 (IBM, 
Armonk, NY, USA). Analyses were based on two-tailed 
hypothesis tests, and a value of p < 0.05 was considered to 
indicate statistical significance.
RESULTS
Characteristics of Patients and Cells Infused for ABMI
Twenty patients underwent screening tests, one of 
whom was excluded according to the exclusion criteria. 
Therefore, 19 patients underwent ABMI and were fol-
lowed up. The baseline characteristics of the patients are 
shown in Table 1. The mean age of the 9 male and 10 
female patients was 52 years. Eighteen patients (94.7%) 
had B-viral LC, and one had alcoholic LC. Sixteen 
patients had stable hepatitis B with (14 patients) or with-
out (2 patients) antiviral medications. Two patients started 
antiviral medications, and four patients experienced viral 
breakthrough during the follow-up period; the antivi-
ral medications of these patients were changed. Three 
patients had HCC prior to undergoing ABMI. Two 
patients underwent resection of HCC, and one patient 
received transarterial chemoembolization and sustained 
a complete response for >2 years. Fourteen patients 
(73.7%) had ascites before ABMI. The average CP score 
of the patients was 7.6, and all but one had cirrhosis of 
CP class B.
The characteristics of infused cells are shown in 
Table 2. The mean cell number per unit body weight 
was 0.925 ´  108 cells/kg. The average final cell volume 
after red blood cell (RBC) depletion and concentra-
tion was 124.1 ml. These cells were infused over a 1-h 
period, and no adverse reactions were noted. The major-
ity of the cell population was CD45+ hematopoietic stem 
cells (83.43%), while CD133+, CD117+, and CD34+ 
hematopoietic stem cells each made up ~1% of the popu-
lation. There was no association between cell population 
and hepatic function improvement.
Table 1. Baseline Characteristics of Patients (N = 19)
Variable Values
Age (years) 52 ± 8
Sex (male/female) 9:10
Etiology (HBV/alcohol) 18:1
Ascites 14 (73.7)
AST (IU/L) 46 (28–196)
ALT (IU/L) 39.5 (21–130)
Albumin (g/dl) 2.9 ± 0.4
Total bilirubin (mg/dl) 1.6 ± 0.6
Cholesterol (mg/dl) 123.2 ± 27.1
Hemoglobin (g/dl) 11.6 ± 1.5
Prothrombin time (%) 70.9 ± 11.2
Child–Pugh score 7.6 ± 1.2
Child–Pugh class (B/C) 18:1
ICG R15 (%) 48.0 ± 13.8
Liver stiffness (kPa)* 26.5 ± 11.5
Variables are expressed as mean ± standard deviation, median (range), 
or n (%). HBV, hepatitis B virus; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; ICG, indocyanine green clearance test; 
kPa, kilopascal.
*Liver stiffness was measured only in the patients without ascites 
(n = 5).
Table 2. Composition of Infused Bone Marrow Cells
Variables Values
Total infused nucleated cells/weight  
 (×108 cells/kg)
0.9250 ± 0.3244
CD34+ cells (%) 0.64 ± 0.44
CD45+ cells (%) 83.43 ± 15.91
CD117+ cells (%) 0.85 ± 0.59
CD133+ cells (%) 1.10 ± 1.00
Variables are expressed as mean ± standard deviation. CD, cluster of 
differentiation.
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Changes in Liver Function
The results of serial blood tests after ABMI were com-
pared to those before ABMI. The results of selected tests 
related to liver function are shown in Figure 1. The mean 
serum level of albumin before ABMI was 2.9 g/dl. The 
mean albumin level during the 6 months before ABMI 
was also 2.9 g/dl, and this was not improved with con-
servative management, including use of antiviral agents. 
This gradually and significantly increased to 3.2, 3.3, 3.4, 
and 3.4 g/dl at 3, 6, 9, and 12 months, respectively, after 
ABMI (Fig. 1A). The mean initial level of total bilirubin 
was 1.6 mg/dl, and it did not change significantly after 
ABMI (Fig. 1B). The average prothrombin time before 
ABMI was 70% and improved significantly to 75% at 
6 months and 76% at 9 months after ABMI (Fig. 1C). 
The mean total cholesterol level increased from 123 to 
134 mg/dl at 3 months and to 136 mg/dl at 6 months after 
ABMI (Fig. 1D). Hemoglobin levels increased signifi-
cantly from 11.6 g/dl before ABMI to 12.3, 12.5, 12.5, 
and 13.1 g/dl at 3, 6, 9, and 12 months, respectively, after 
ABMI (Fig. 1E). The initial average CP score was 7.6 and 
improved significantly after 6, 9, and 12 months to 6.8, 
6.7, and 6.7, respectively (Fig. 1F).
Twelve patients (63.2%) had achieved CP class A 
within 1 year. This improvement was significantly related 
only to an increased liver volume after 6 months ( p < 0.13). 
At 24, 36, and 60 months, 11, 7, and 5 patients, respec-
tively, had achieved CP class A without LT or death. 
Among the five patients with CP class A at 60 months, 
two had improved to that class after 24 months, while the 
others were of that class the full 60 months.
Changes in Liver Volume and Fibrosis
All patients underwent MRI at screening, but two 
patients refused to undergo MRI at the 6-month follow-up. 
The reconstructed liver volume of the other 17 patients 
increased significantly at 6 months after ABMI ( p = 0.049) 
(Fig. 2A). Eleven patients (64.7%) showed an increased 
liver volume compared to baseline. The greatest increase 
compared to baseline (Fig. 2B, left) was 42% after 6 
months (Fig. 2B, right).
According to pathologic evaluation of serial biopsies, 
ABMI did not lead to resolution of cirrhosis. To compare 
changes in liver fibrosis, available unstained liver tissues 
were analyzed in terms of the level of collagen deposition. 
The percentage of portal collagen decreased significantly 
at 3 months (Fig. 3A). The septal collagen percentage 
showed a decreasing tendency after ABMI (Fig. 3B), as 
did the total fibrillar tissue collagen (fibrosis other than 
portal and septal fibrosis) percentage (Fig. 3C).
Long-Term Clinical Outcomes
Patients were followed up for a median of 66 months 
after ABMI (range: 2–113 months). Five patients (26.3%) 
underwent LT at 5–39 months, five patients (26.3%) 
died, and three patients (15.3%) were lost to follow-up. 
A survival curve of patients who did not undergo LT or 
die is shown in Figure 4A. The median duration of sur-
vival without LT was 48 months. Five patients died due 
to pneumonia (n = 3), lymphoma (n = 1), and spontaneous 
bacterial peritonitis (n = 1). Three patients (15.8%) were 
lost to follow-up at 22, 31, and 32 months; these patients 
did not exhibit deterioration of liver function at their final 
follow-up.
HCC developed in five patients (26.3%) after ABMI. 
One patient had previously undergone HCC  resection, 
while the others developed HCC at 16, 17, 18, and 
56 months after ABMI. Four patients underwent suc-
cessful nonsurgical treatment, and one received elective 
LT. In HCC-naive patients, the cumulative incidence of 
HCC at 3 and 5 years was 23.1% and 35.9%, respectively 
(Fig. 4B). The patient with HCC recurrence exhibited 
improved liver function but was diagnosed with lym-
phoma at 49 months. The lymphoma was thought to be 
hepatitis B virus (HBV)-related lymphoproliferative dis-
ease and led to death of the patient.
Figure 2. Changes in liver volume calculated using magnetic resonance imaging (MRI) scans at 6 months after ABMI. (A) Liver 
volume significantly increased after ABMI (p = 0.049). (B) Image of the most enlarged liver section image showed a 42% increase in 
liver volume and decreased ascites at 6 months after ABMI (right) compared to baseline (left). *p < 0.05.
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In one patient who showed improvement to CP class 
A, cancer of the sigmoid colon was found during routine 
colonoscopy at 18 months after ABMI. This was removed 
by endoscopic mucosal resection, and no further recur-
rence or hepatic function deterioration was noted.
DISCUSSION
The findings of this work suggest that ABMI for 
decompensated LC could improve liver function and 
decrease the collagen level in liver tissue transiently and 
inconspicuously, although LC itself was not resolved. 
Some patients successfully bridged to LT, and others 
sustained an improved state without significant adverse 
events related to ABMI. However, some patients devel-
oped infection or HCC after >5 years.
We evaluated the effects of ABMI using various 
parameters, while other studies using BMCs or MSCs 
for LC have focused on blood test results. Functional 
changes were assessed by determining serum levels of 
albumin and CP class. Pathologic and computer-assisted 
evaluation of fibrosis and liver tissue were performed. 
Regenerative changes were assessed by measuring liver 
volume. The patients showed improvement in terms of 
biochemical parameters, CP class, and liver regeneration, 
as indicated by an increased liver volume.
A recent meta-analysis of autologous BM transplan-
tation in decompensated livers showed a benefit after 
1 year27. Previous studies of cell therapy have reported 
only short-term effects because long-term monitoring of 
subjects was not possible. In the early stage of cell ther-
apy research, long-term safety was a matter of concern 
because, in contrast to chemotherapeutic agents, injected 
stem cells have long half-lives, the possible ability to 
transdifferentiate and/or repopulate, and no modulat-
ing manner after injected. While use of autologous cells 
prevents adverse immunologic reactions, their effects on 
cancer development are unclear. Therefore, maintenance 
of the therapeutic effects of cell therapy and its influence 
on cancer development are unresolved issues.
In this cohort, three patients with HCC underwent 
successful treatment before ABMI. These patients were 
included in this study because they had no recurrence of 
HCC for 2 years before ABMI and showed no HCC on 
screening MRI. Among these three patients, one experi-
enced HCC recurrence at 10 months after ABMI. This 
patient underwent successful HCC treatment; however, 
lymphoma developed 49 months after ABMI. A hema-
tologist speculated that the lymphoma was likely related 
to HBV infection, as reported previously28. However, it is 
also possible that ABMI contributed to the development 
of lymphoma. Because lymphoproliferative disease usu-
ally progresses rapidly, the 4 years between ABMI and 
the lymphoma diagnosis means that a causal relationship 
is possible but unlikely. Further research is warranted to 
Figure 3. Collagen deposition as determined by a computer-
assisted, staining-free method for assessment of liver fibro-
sis. (A) Percentage portal collagen was significantly lower at 
3 months. (B) Septal collagen showed a decreasing tendency 
over time. (C) Total fibrillar tissue collagen (fibrosis other than 
portal and septal fibrosis) percentage also showed a decreasing 
tendency over time. *p < 0.05.
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resolve this issue. HCC did not recur in the other two 
patients with HCC before ABMI.
Other than the patient discussed above, HCC was 
newly diagnosed in four patients after ABMI. Because 
they had undergone regular evaluations, HCC was found 
at an early stage and treated successfully. Only one patient 
considered LT for treatment of HCC; the others elected 
nonsurgical treatments. The 5-year cumulative risk of 
HCC has been reported to be 15% in compensated HBV-
related LC in a high-endemic area29, and patients with 
a more advanced CP class had a higher risk of HCC30. 
The rate of newly developed HCC in these patients 
(4/16, 25%) is comparable with that reported previously. 
However, the relatively high incidence of HCC within 
2 years after ABMI warrants further study.
Infection was the most frequent cause of death in 
our patients. Two patients with improved liver function 
expired from uncontrolled pneumonia, and two patients 
without improvement died due to pneumonia and sponta-
neous bacterial peritonitis. To the best of our knowledge, 
no previous study has evaluated the frequency of infec-
tions after cell therapy in LC patients.
The limitations of this study were its single-arm design 
and inclusion of a small population. However, this study 
was started as an exploratory pilot trial in its early days 
of cell therapy. From the result of this trial, a random-
ized controlled trial is underway and is expected to pro-
vide more confirmative evidence in terms of therapeutic 
effects and influence on cancer development.
Our results suggest that ABMI for decompensated LC 
could improve liver function and volume over the short 
Figure 4. Survival curve without liver transplantation (LT) and cumulative rate of hepatocellular carcinoma (HCC) development. 
(A) The median survival duration without LT was 48 months. (B) In HCC-naive patients, the cumulative rate of HCC development at 
3 and 5 years was 23.1% and 35.9%, respectively.
term. Over the long term, while some patients main-
tained improved liver function, HCC developed in other 
patients. Further studies of long-term follow-up cohorts 
after cell therapy for LC are warranted.
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